Drug Discovery AI Talk

Virtual Biology's Reality Check

Biohub's Virtual Biology Initiative just expanded to $1.8 billion — backed by the DOE, NIH, Google DeepMind, Isomorphic Labs, and Meta — to build the data foundations for

#76. AI's Phase III Moment

On September 10, 2026, Insilico Medicine dosed the first patient in the Phase III GENESIS-IPF-3 trial of rentosertib (ISM001-055) for idiopathic pulmonary fibrosis - the

#75. The AI Patent Landscape 2026

In this episode, we examine how AI-native biotechnology companies are reshaping drug discovery through the lens of their intellectual-property portfolios. The evidence su

#74. Is Drug Discovery AI Safe?

In this podcast, we study how integrating agentic AI into autonomous wet labs promises rapid therapeutic innovation, while connecting autonomous models directly to physic

#73. The Triumph of Daraxonrasib

For decades, KRAS stood as oncology’s archetypal “undruggable” target—a powerful cancer driver with no obvious pocket for conventional medicines to grasp. This episode ex

#72. 2026 Emerging Trends

In this podcast, we show a pivotal shift in 2026 for AI drug discovery toward integrated, AI-native R&D systems that move beyond simple algorithmic tasks to form closed-l

#71. Magic Wands

In this episode, we critically examine whether AI drug discovery is solving the hardest problems in medicine—or simply making the easier ones faster. At the center of the

#70. Beyond AlphaFold

In this episode, we venture beyond protein structure prediction into the messy, stochastic reality of modeling the virtual cell. We examine why biology still lacks an Alp

#69. CollaboFest

What if we could turn a spark of biological insight into a real-world, life-saving treatment? That is the core mission of CollaboFest, an innovative initiative designed t

#68. Molecular Glues in Therapy

In this episode, we explore the rapid evolution of molecular glues, a breakthrough in targeted protein degradation that stabilizes protein interactions to treat previousl

#67. Does Size Matter?

In this episode, we examine whether increasing the size and depth of neural networks truly enhances molecular property prediction compared to traditional machine learning

#66. Quantitative Systems Pharmacology

In this episode, we explore the evolving role of Quantitative Systems Pharmacology (QSP) in drug development, particularly as a mechanistic alternative to traditional ani

#65. Orbiting around Big Pharma

In this episode, we explore Lilly TuneLab as a major signal of where AI drug discovery may be heading: toward powerful platform ecosystems that combine proprietary pharma

#64. Foundation Models

In this episode, we explore the surge of foundation models (FMs) within pharmaceutical research, noting that over 200 such models were published by early 2025. Unlike tra

#63. The Era of NAMs

This podcast explores the transformative shift toward New Approach Methodologies (NAMs), which utilize human-relevant experimental and computational systems to modernize

#62. Predicting Toxicity

In this episode, we investigate the significant evolution of AI-driven toxicity prediction, detailing how the field has shifted from simple statistical models to sophisti

#61. AI Era Evidence Flywheel

 In this episode, Dr. Jake Chen provides his narrative review and advocates for a fundamental shift in pharmaceutical research, moving away from inefficient trial-and-err

#60. Cracking the "Undruggable" Target

Welcome to today's episode, where we dive into a monumental breakthrough in oncology, i.e., cracking the "undruggable" KRAS mutation. For decades, pancreatic cancer has b

#59. Drug Discovery AI Teammates

AI isn't replacing scientists in the lab — it's joining the team. This episode unpacks "capability complementarity," the framework where human creativity and contextual j

#58. Do We Need Mavericks?

In this episode, we explore the evolution of leadership within the field of AI-driven drug discovery, identifying key figures who are reshaping how medicines are develope